Skip header and navigation

3 records – page 1 of 1.

5-Aminosalicylate (5-ASA)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Responsibility
Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Phyllis Durning, RN
Revised by: Alison Harding, B.Sc.
Pamphlet Number
1483
Less detail

Ustekinumab (Stelara) therapy for Crohn's disease

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. QEII. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1695
Available Online
View Pamphlet
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing thi…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Gastroenterology
Editor
Stewart, Jennifer (RN, CCRP)
Leddin, Desmond, J. (MD, Gastroenterology)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Crohn Disease - drug therapy
Subjects (LCSH)
Crohn's disease
Gastrointestinal agents
Abstract
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Alison Harding, BSc; Gastroenterology
Pamphlet Number
1695
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Allison Harding BSc & Jennifer Stewart RN, CCRP; Division of Gastroenterology
Pamphlet Number
1623
Less detail